Operaciones de insiders

EDGAR

Evoke Pharma Inc

Operaciones informadas por directores, ejecutivos y titulares de más del 10 % en los Formularios 3, 4 y 5 de la SEC, leídas del XML de cada presentación. Los códigos y su redacción son los de la SEC.

El Formulario 4 debe presentarse dentro de los dos días hábiles posteriores a la operación, por lo que las más recientes pueden no estar presentadas aún.

Ventana: operaciones con fecha desde el 16 nov 2025.

Compras en el mercado abierto (código P)
0 operaciones, — acciones
Ventas en el mercado abierto (código S)
0 operaciones, — acciones

Los totales suman las operaciones presentadas que se listan; cuentan lo informado y no miden una dirección.

Mostrando 1–37 de 37

Operaciones de insiders, las más recientes primero, según los Formularios 3, 4 y 5 de la SEC
FechaTitular informanteCódigoAdquirido o enajenadoAccionesPrecio por acción, según lo presentadoValor (derivado)Acciones poseídas despuésDirecta o indirectaCasilla de la Regla 10b5-1NotasFuente
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Enajenado (D)148.15311,00
1.629.683

Derivado: acciones × precio por acción. Valor exacto 1629683.00.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor derivado: Prefunded Warrants — subyacente Common Stock (433.962) — precio de ejercicio 0.0001
Enajenado (D)433.96210,999
4.773.148,038

Derivado: acciones × precio por acción. Valor exacto 4773148.038.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor derivado: Series A Common Stock Purchase Warrants — subyacente Common Stock (117.019) — precio de ejercicio 8.16
Enajenado (D)117.0194,71
551.159,49

Derivado: acciones × precio por acción. Valor exacto 551159.49.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor derivado: Series C Common Stock Purchase Warrants — subyacente Common Stock (117.019) — precio de ejercicio 8.16
Enajenado (D)117.0194,71
551.159,49

Derivado: acciones × precio por acción. Valor exacto 551159.49.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor derivado: Amended Series A Common Stock Purchase Warrants — subyacente Common Stock (158.531) — precio de ejercicio 0.01
Enajenado (D)158.53110,99
1.742.255,69

Derivado: acciones × precio por acción. Valor exacto 1742255.69.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 19 dic 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor derivado: Amended Series C Common Stock Purchase Warrants — subyacente Common Stock (250.627) — precio de ejercicio 0.01
Enajenado (D)250.62710,99
2.754.390,73

Derivado: acciones × precio por acción. Valor exacto 2754390.73.

0Indirecta (I) See FootnoteNo
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir presentación 0001104659-25-123156 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1218) — precio de ejercicio 5.41
Enajenado (D)1218——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322642 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 4.45
Enajenado (D)5833——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322642 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1218) — precio de ejercicio 3.453
Enajenado (D)1218——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322642 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1479) — precio de ejercicio 5.41
Enajenado (D)1479——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322643 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (8750) — precio de ejercicio 4.45
Enajenado (D)8750——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322643 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1291) — precio de ejercicio 3.453
Enajenado (D)1291——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322643 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1187) — precio de ejercicio 5.41
Enajenado (D)1187——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322641 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 4.45
Enajenado (D)5833——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322641 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1187) — precio de ejercicio 3.453
Enajenado (D)1187——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322641 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1250) — precio de ejercicio 5.41
Enajenado (D)1250——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322638 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 4.45
Enajenado (D)5833——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322638 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1250) — precio de ejercicio 3.453
Enajenado (D)1250——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322638 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1218) — precio de ejercicio 5.41
Enajenado (D)1218——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322639 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 4.45
Enajenado (D)5833——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322639 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1187) — precio de ejercicio 3.453
Enajenado (D)1187——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322639 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 5.51
Enajenado (D)5833——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322645 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1125) — precio de ejercicio 3.453
Enajenado (D)1125——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322645 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (17.291) — precio de ejercicio 5.27
Enajenado (D)17.291——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322644 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (11.000) — precio de ejercicio 4.45
Enajenado (D)11.000——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322644 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (64.840) — precio de ejercicio 5.27
Enajenado (D)64.840——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322637 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (70.000) — precio de ejercicio 4.45
Enajenado (D)70.000——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322637 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (17.291) — precio de ejercicio 5.27
Enajenado (D)17.291——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322640 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (13.000) — precio de ejercicio 4.45
Enajenado (D)13.000——0Directa (D) No
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322640 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (5833) — precio de ejercicio 5.26
Enajenado (D)5833——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322646 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 17 dic 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (1155) — precio de ejercicio 3.453
Enajenado (D)1155——0Directa (D) No
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir presentación 0001193125-25-322646 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)133——0Directa (D) No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322642 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)2330——0Indirecta (I) By Garner Investments, L.L.C.No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322643 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)27——0Directa (D) No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322639 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)360——0Directa (D) No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322644 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)15.509——0Directa (D) No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322637 Leído del XML de la presentación Disputar esta fila
16 dic 2025 Presentado el 17 dic 2025Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Enajenado (D)11.815——0Directa (D) No
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir presentación 0001193125-25-322640 Leído del XML de la presentación Disputar esta fila

Titulares institucionales (Formulario 13F)

No hay en el almacén ninguna posición del Formulario 13F atribuida a este emisor. Un titular aún sin vincular o sin presentar está ausente, no en cero.

Titulares del 5 % (Anexos 13D y 13G)

Aquí se leen los anexos presentados en el formato estructurado de la SEC (desde finales de 2024). Los anteriores son texto libre y no se leen.

Titulares del 5 %, el evento más reciente primero, según lo presentado
TitularPorcentaje de la claseAcciones en poderFecha del eventoFormularioFuente
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00,0012/17/2025 Presentado el 19 dic 2025SCHEDULE 13D/AEnmienda 5Abrir presentación 0001104659-25-123157 Disputar esta fila
Harkey Wilmot B. Common Stock, par value $0.0001 per share00,0012/17/2025 Presentado el 19 dic 2025SCHEDULE 13D/AEnmienda 5Abrir presentación 0001104659-25-123157 Disputar esta fila
Mack Daniel Common Stock, par value $0.0001 per share00,0012/17/2025 Presentado el 19 dic 2025SCHEDULE 13D/AEnmienda 5Abrir presentación 0001104659-25-123157 Disputar esta fila
Morgan Stanley Common Stock0.03111/30/2025 Presentado el 5 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000895421-25-000595 Disputar esta fila
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 Presentado el 5 dic 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000895421-25-000595 Disputar esta fila
Klein Roger M. Common Stock, par value $0.0001 per share10.5163.000,0011/04/2025 Presentado el 12 nov 2025SCHEDULE 13DAbrir presentación 0001651175-25-000007 Disputar esta fila
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129.000,0011/04/2025 Presentado el 12 nov 2025SCHEDULE 13DAbrir presentación 0001651175-25-000007 Disputar esta fila
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Presentado el 4 nov 2025SCHEDULE 13D/AEnmienda 4Abrir presentación 0001104659-25-106048 Disputar esta fila
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Presentado el 4 nov 2025SCHEDULE 13D/AEnmienda 4Abrir presentación 0001104659-25-106048 Disputar esta fila
Mack Daniel Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Presentado el 4 nov 2025SCHEDULE 13D/AEnmienda 4Abrir presentación 0001104659-25-106048 Disputar esta fila
Morgan Stanley Common Stock10.5163.71808/31/2025 Presentado el 8 sept 2025SCHEDULE 13GAbrir presentación 0000895421-25-000528 Disputar esta fila
Morgan Stanley Smith Barney LLC Common Stock10.5163.71808/31/2025 Presentado el 8 sept 2025SCHEDULE 13GAbrir presentación 0000895421-25-000528 Disputar esta fila

El porcentaje es de la clase que indica la presentación, según lo declaró el titular. Los miembros de un grupo informan cada uno las acciones del grupo, por lo que las filas no se suman.

Qué se leyó

2.092.408 presentaciones leídas, del 14 jun 2004 al 13 nov 2026: Formularios 3, 3/A, 4, 4/A, 5, 5/A.

Algunos años pueden estar incompletos mientras se sigue leyendo el archivo. Un año con pocas presentaciones aquí no afirma que se hicieran pocas.

Presentaciones leídas, por año de presentación
Año de presentaciónPresentaciones leídas
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024185.386
2025235.520
2026254.737

Las presentaciones anteriores a que la SEC exigiera XML se listan, pero no se extraen.

Volver a Evoke Pharma Inc